Sign in
Enrolling by invitationNo phase

Two methylprednisolone dose levels for Graves' ophthalmopathy, an eye disease linked to thyroid disease

Compares higher and lower methylprednisolone doses in people newly diagnosed with active Graves' ophthalmopathy.

Key facts

Who runs it
Zou Junjie
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO)
Status
Enrolling by invitation
People taking part
120 people, planned
Started
1 Jan 2025
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • High-Dose Methylprednisolone
  • Low-Dose Methylprednisolone
Record updated
22 May 2025

Who can take part

Age
25 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Voluntarily accept the study and sign the informed consent form
  • Age between 25 and 70 years old at the time of enrollment, both males and females are eligible
  • Newly diagnosed Graves' ophthalmopathy, moderate to severe active patients. The criteria for moderate to severe GO are: ① eyelid retraction ≥2mm; ② moderate to severe involvement of orbital soft tissues; ③ proptosis ≥20mm; ④ periodic or persistent diplopia. Meeting one of the above four criteria is sufficient; The criteria for active GO are: CAS score ≥4 points. Scoring criteria: ① spontaneous retro-ocular pain; ② pain on eye movement; ③ conjunctival congestion; ④ eyelid congestion; ⑤ chemosis of the conjunctiva; ⑥ swelling of the caruncle; ⑦ eyelid edema. One point is recorded for each of the above seven symptoms if present, and zero if absent
  • The onset of Graves' ophthalmopathy does not exceed 12 months, and those who have not been treated with glucocorticoids or other immunosuppressive agents
  • Women of childbearing age must use effective contraceptive measures
  • At the time of screening, hyperthyroidism in the study subjects should be basically controlled. Thyroid function should be normal or only mildly abnormal, defined as FT4 and FT3 levels within 50% of the upper and lower limits of the normal range. Mild thyroid dysfunction should be corrected as much as possible, and a normal thyroid function state should be maintained throughout the clinical trial period

Who cannot take part

  • Individuals with optic nerve involvement requiring orbital decompression surgery. Defined as a decrease in vision by more than two lines in the past six months, or new visual field defects, or color vision deficiencies
  • Severe cardiac diseases such as myocardial infarction, unstable angina, and chronic heart failure
  • Individuals with a history of alcohol abuse or drug use
  • Patients with psychiatric disorders, or those who are non-cooperative
  • Known liver diseases, or alanine transaminase (ALT) levels more than 1.5 times the upper limit of normal
  • Chronic kidney disease, or serum creatinine >135 umol/L (>1.5 mg/dL)
  • Individuals with diabetes, and HbA1c >9.0%
  • Subjects with a white blood cell count <4.0×10\^9/L, or a platelet count <80×10\^9/L
  • Significant anemia (hemoglobin levels <110 g/L in males, <100 g/L in females)
  • Pregnant women, women who are breastfeeding, or women planning to become pregnant during the trial period
  • Corneal ulcers, contraindications for glucocorticoid treatment

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 25 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study plans to include newly diagnosed, active, moderate to severe Graves' ophthalmopathy patients, divided into a high-dose group (methylprednisolone 500mg, D1-3, once every 4 weeks) and a low-dose group (methylprednisolone 1mg/kg, D1-3, once every 4 weeks), with a treatment duration of 24 weeks to compare the efficacy and safety of the two groups. Additionally, this study will extend the follow-up to 48 weeks to observe the recurrence rate after treatment in both groups, exploring the heterogeneity of the active course of Graves' ophthalmopathy.

The 2 groups in the trial

  • a high-dose groupExisting treatment, for comparison

    methylprednisolone 500mg, D1-3, once every 4 weeks

    Treatment: High-Dose Methylprednisolone

  • a low-dose groupTreatment being tested

    methylprednisolone 1mg/kg, D1-3, once every 4 weeks

    Treatment: Low-Dose Methylprednisolone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Different Methylprednisolone Pulse Therapy Regimens for the Treatment of Graves' Ophthalmopathy
Plain-language title
Two methylprednisolone dose levels for Graves' ophthalmopathy, an eye disease linked to thyroid diseaseGenerated from the registry record. The registry title is the official one.
Criteria questions
Built from NCT06693856, who can take part
Record updated
22 May 2025